ArticlePloS one2014
Molecular epidemiology of carbapenem non-susceptible Acinetobacter baumannii in France.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Multidrug resistant Acinetobacter baumannii shows epidemiology and transmission patterns in a China tertiary hospital ICU.Scientific reports · 2026Article
- β-Lactamase diversity inAntimicrobial agents and chemotherapy · 2025Article
- Epidemiology, resistance genomics and susceptibility ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Multiple host colonization and differential expansion of multidrug-resistant ST25-Acinetobacter baumannii clades.Scientific reports · 2023Article
- Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2022Article
- Distribution of Carbapenemase Genes among Carbapenem-Non-SusceptibleAntibiotics (Basel, Switzerland) · 2022Article
- Variants of TnMicrobiology spectrum · 2022Article
- Pan-Resistome Insights into the Multidrug Resistance ofAntibiotics (Basel, Switzerland) · 2021Article
- A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Prevalence and Characterization of Carbapenem-Hydrolyzing Class D β-Lactamase-ProducingFrontiers in microbiology · 2020Article
- Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
- Emergence, molecular mechanisms and global spread of carbapenem-resistantMicrobial genomics · 2019Review
- Deciphering Multifactorial Resistance Phenotypes inMolecular & cellular proteomics : MCP · 2018Article
- The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.Antimicrobial resistance and infection control · 2018Article
- Clonal diversity and detection of carbapenem resistance encoding genes among multidrug-resistantAntimicrobial resistance and infection control · 2017Article
- Clonal Spread of Acinetobacter baumannii Sequence Type 25 Carrying blaOXA-23 in Companion Animals in France.Antimicrobial agents and chemotherapy · 2017Article
- Insights on the Horizontal Gene Transfer of Carbapenemase Determinants in the Opportunistic Pathogen Acinetobacter baumannii.Microorganisms · 2016Review
- Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015Article
- Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia.Annals of clinical microbiology and antimicrobials · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Acinetobacter baumannii have emerged globally. The objective of this study was to investigate the epidemiology, clonal diversity and resistance mechanisms of imipenem non-susceptible A. baumannii isolates in France. Between December 2010 and August 2011, 132 notifications were collected, including 37 outbreaks corresponding to 242 cases (2 to 55 per cluster). Multilocus sequence typing, pulsed-field gel electrophoresis (PFGE) and characterisation of carbapenemase-encoding genes were performed on 110 non-repetitive isolates. Gene blaOXA-23 was the most frequently detected (82%), followed by blaOXA-24 (11%) and blaOXA-58 (7%). Eleven sequence types (ST) were distinguished, among which sequence types ST1, ST2 (64%), ST20, ST25, ST85 and ST107. Isolates from epidemiological clusters had the same ST and resistance genes, indicating probable transmission within centres. In contrast, PFGE types of isolates differed among centres, arguing against transmission among centers. This study provides the first epidemiological snapshot of the population of A. baumannii with reduced susceptibility to carbapenems from France, and further underlines the predominance of international clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.